What Would You Do with a Fluorescent Green Pig?: How Novel Transgenic Products Reveal Flaws in the Foundational Assumptions for the Regulation of Biotechnology

Lawrence, Sheryl
February 2007
Ecology Law Quarterly;2007, Vol. 34 Issue 1, p201
Academic Journal
The Federal Food, Drug, and Cosmetics Act (FDCA) and the Coordinated Framework for the Regulation of Biotechnology are the primary federal tools for oversight of the products of genetic modification. Since their enactment, tremendous advancements in biotechnology have resulted in the creation of novel transgenic organisms, significantly unlike any pre-existing life form. The innovative nature of these transgenic products challenges fundamental assumptions of the FDCA and the Coordinated Framework. The first of these key assumptions is that the categories of "foods" and "drugs" are cleanly separable, and thus can be regulated through entirely different pathways, The FDCA and the Coordinated Framework also assume that genetically modified products do not pose inherent risks of environmental harm requiring regulatory oversight. On this basis, the United States has established a bifurcated system for the regulation of foods and drugs, in which drugs are subjected to much more rigorous scrutiny than food or industrial products. However, basing risk assessment for a novel transgenic organism on this classification places far too much weight on a distinction that is oblivious to the innate features of the transgenic product that present potential risk. Many transgenic organisms will present multiple usage possibilities, whether food, drug, or industrial, creating a strong potential for duplicative regulatory efforts, and for widespread unapproved uses of a product once it becomes commercially available. This focus on classification as a prerequisite for regulatory review by the Food and Drug Administration (FDA) also leaves the door open for creatures and products intended for industrial use, or as pets, to enter the marketplace without regulatory scrutiny. In addition, experience with transgenic organisms demonstrates the inadequacy of containment measures for both genetically modified plants and animals, highlighting real risks to ecology, to native species, and to other life forms posed by the unintended introduction of novel creatures into the wild. Twenty years of regulation has shown that the Coordinated Framework's regulatory structure is too inflexible, and the existing laws are too weak, to adequately address the challenges of biotechnology regulation today. To address faults in the existing regulatory structure, this Comment considers the FDA's creation of the Office of Combination Products to coordinate the regulation of interrelated classes of conventional medical products as a model for the development of a similar office overseeing the growth and marketing of genetically modified organisms and their derivative products. In addition, this Comment proposes amendments to the FDCA and the Coordinated Framework that identify and address the previously unforeseen risks presented by evolving advances in genetic engineering. Only by casting off the blinders of the Coordinated Framework and allowing federal regulators to seek out and consider the entirety of the risk potential of each novel transgenic organism can there be real confidence in the FDA's ability to broadly protect public health and safety in this amazing technological arena.


Related Articles

  • Are You Eating Test-Tube Food?  // Prevention;May2000, Vol. 52 Issue 5, p122 

    Questions the consumption of genetically engineered foods, also known as Frankenfoods. How genetic engineering differs from traditional crop breeding; Lack of safety measures, labeling and accountability required by the United States Food and Drug Administration (FDA) for such companies;...

  • The FDA's Regulation Of Health Economic Information. Neumann, Peter J.; Claxton, Karl // Health Affairs;Sep/Oct2000, Vol. 19 Issue 5, p129 

    Discusses the impact of Section 114 of the Food and Drug Administration (FDA) Modernization Act of 1997 on the pharmaceutical industry. Manner by which health economic information may be classified under the new rules; Drawbacks and benefits in allowing drug firms to make economic claims about...

  • Anti-biotech groups push for labeling.  // Western Farm Press Exclusive Insight;5/14/2012, p10 

    The article presents the call for mandatory biotechnology labeling by the California Right to Know Campaign if the food has been produced using genetically engineered products. It states that the referendum's approval would mean necessary labeling of genetically manufactured items and disallow...

  • NRC Reports on Concerns About Animal Biotechnology.  // Journal of Environmental Health;Jan/Feb2003, Vol. 65 Issue 6, p42 

    Focuses on the report of the National Research Council (NRC) on hazards associated with animal biotechnology, submitted to the U.S. Food and Drug Administration. Concerns of NRC committee regarding the ability of certain genetically engineered organism to escape and reproduce in natural...

  • FOOD AND DRUG LAW AS INTELLECTUAL PROPERTY LAW: HTSTORICAL REFLECTIONS. Swanson, Kara W. // Wisconsin Law Review;2011, Vol. 2011 Issue 2, p331 

    This Article returns to the turn of the twentieth century to consider food and drug law as intellectual property law. Today, Americans are engaged in two separate debates about food and drugs, one centering on safety and the effectiveness of the Food and Drug Administration, and the other on...

  • Friends in the US Senate Need Our Support to Strengthen the Influence of DSHEA Within the FDA. Walker, Randall; Walker, Morton; Miller, Clinton Ray // Townsend Letter for Doctors & Patients;Jan2004, Issue 246, p143 

    Focuses on the enactment of the Dietary Supplement and Health Education Act of 1994 by the 103rd Congress in the U.S. Role of U.S. Food and Drug Administration under the legislation; Effect of the legislation on pharmaceutical industry; Availability of the new products to Complementary and...

  • FDA Law Enforcement: Critical to Product Safety. Rados, Carol // FDA Consumer;Jan/Feb2006, Vol. 40 Issue 1, p21 

    The article discusses the importance of laws enforced by the U.S. Food and Drug Administration (FDA) in promoting product safety. It presents the process of the enforcement of the laws, including outreach programs initiated by the FDA. The authority of FDA inspectors in enforcing the laws is...

  • APhA-APRS. Williams, Karl G. // Journal of the American Pharmacists Association: JAPhA;Sep/Oct2010, Vol. 50 Issue 5, p560 

    The article discusses new provisions in the United States Food and Drug Administration Amendments Act (the Act) . The Act authorizes the Food and Drug Administration (FDA) to require submission of a proposed risk evaluation and mitigation strategies (REMS) by manufacturers any time that risks of...

  • New Proposal Seeks to Increase FDA Resources and Authority. Scott, Alex // Chemical Week;5/5/2008, Vol. 170 Issue 14, p33 

    The article reports on the introduction of the U.S. Food and Drugs Authority (FDA) Globalization Act of 2008 by Democrat Representative John Dingell of Michigan that aims to increase FDA resources and authority to protect the food and drug supplies in the country. The bill also requires FDA to...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics